Emerging Data for MDS
Congress to Clinic: Expert Takeaways on Emerging Data for MDS

Released: July 08, 2024

Expiration: July 07, 2025

Courtney DiNardo
Courtney DiNardo, MD, MSCE
Brady L. Stein
Brady L. Stein, MD, MHS
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1
Course Completed

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the  EHA 2024 Congress including:

  • COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low–, low- or intermediate-risk MDS
  • Real-world dose-escalation and outcomes among patients with lower-risk MDS receiving luspatercept in clinical practice
  • Phase II ASTREON trial―preliminary safety/efficacy of oral azacitidine in low-/intermediate, intermediate-risk, MDS
  • Phase III IMerge: overall survival and transfusion independence with imetelstat in patients with low-risk or intermediate-1–risk MDS  
  • Phase III ENHANCE study of magrolimab plus azacitidine vs azacitidine plus placebo for higher-risk MDS
  • Oral decitabine/cedazuridine plus venetoclax vs oral decitabine/cedazuridine alone in high-risk MDS: a propensity score analysis